Angiotensin II

Generic Name
Angiotensin II
Brand Names
Giapreza
Drug Type
Biotech
Chemical Formula
-
CAS Number
4474-91-3
Unique Ingredient Identifier
M089EFU921
Background

Angiotensin II is under investigation for the treatment of Sepsis, Septic Shock, Diabetes Mellitus, and Acute Renal Failure. Angiotensin II has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy.
...

Indication

Angiotensin II is a vasoconstrictor indicated for increasing blood pressure in adults with septic or other distributive shock .

Associated Conditions
Hypotension
Associated Therapies
-
Clinical Trials
Related News

Renin and Renal Biomarker Response to Angiotensin II

First Posted Date
2020-09-22
Last Posted Date
2023-08-09
Lead Sponsor
Alexander Flannery
Target Recruit Count
30
Registration Number
NCT04558359
Locations
🇺🇸

University of Kentucky HealthCare Chandler Medical Center, Lexington, Kentucky, United States

Angiotensin II in the Perioperative Management of Hypotension in Kidney Transplant Recipients

First Posted Date
2020-08-27
Last Posted Date
2022-12-21
Lead Sponsor
University of Illinois at Chicago
Target Recruit Count
20
Registration Number
NCT04529005
Locations
🇺🇸

University of Illinois Hospital and Health Sciences System, Chicago, Illinois, United States

Efficacy and Safety of Angiotensin II Use in Coronavirus Disease(COVID)-19 Patients With Acute Respiratory Distress Syndrome

First Posted Date
2020-05-29
Last Posted Date
2021-08-04
Lead Sponsor
Guy's and St Thomas' NHS Foundation Trust
Target Recruit Count
50
Registration Number
NCT04408326
Locations
🇬🇧

Guy's & St Thomas' Hospital, London, United Kingdom

Angiotensin 2 for Hepatorenal Syndrome

First Posted Date
2019-08-07
Last Posted Date
2024-03-06
Lead Sponsor
University of California, Los Angeles
Registration Number
NCT04048707

Angiotensin II in General Anesthesia

Phase 1
Recruiting
Conditions
Hypertension
Interventions
Drug: Angiotensin II
First Posted Date
2018-11-07
Last Posted Date
2024-04-29
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
60
Registration Number
NCT03733145
Locations
🇺🇸

Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States

A Study of LJPC-501 in Pediatric Patients With Hypotension

First Posted Date
2018-02-13
Last Posted Date
2018-08-07
Lead Sponsor
La Jolla Pharmaceutical Company
Target Recruit Count
2
Registration Number
NCT03431077
Locations
🇺🇸

Investigational Site, San Antonio, Texas, United States

Angiotensin II for Septic Shock Treatment

First Posted Date
2017-10-05
Last Posted Date
2019-01-16
Lead Sponsor
Cairo University
Target Recruit Count
20
Registration Number
NCT03302650
Locations
🇪🇬

Cairo University, Cairo, Egypt

Evaluation of Lysine-Specific Demethylase 1

Not Applicable
Withdrawn
Conditions
Hypertension
First Posted Date
2012-10-08
Last Posted Date
2017-07-12
Lead Sponsor
Brigham and Women's Hospital
Registration Number
NCT01702688
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Vascular Dysfunction in Diabetes: Genes and Hormones

Terminated
Conditions
Diabetes Mellitus
First Posted Date
2012-01-18
Last Posted Date
2022-11-09
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
100
Registration Number
NCT01511042
Locations
🇺🇸

Brigham and Women's Hospital- 221 Longwood Avenue, Boston, Massachusetts, United States

Comparison of Nebivolol and Metoprolol With Exercise and Angiotensin II in Hypertensive Patients

First Posted Date
2012-01-02
Last Posted Date
2020-07-07
Lead Sponsor
University of Texas Southwestern Medical Center
Target Recruit Count
46
Registration Number
NCT01502787
Locations
🇺🇸

UT Southwestern Medical Center, Dallas, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy